Blueprint Medicines Co. (NASDAQ:BPMC) Shares Acquired by Wellington Management Group LLP

Wellington Management Group LLP increased its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 8.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,281,364 shares of the biotechnology company’s stock after purchasing an additional 316,754 shares during the period. Wellington Management Group LLP owned 6.70% of Blueprint Medicines worth $373,421,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of BPMC. Empirical Asset Management LLC purchased a new stake in shares of Blueprint Medicines during the 4th quarter worth approximately $2,348,000. Stephens Inc. AR purchased a new stake in Blueprint Medicines in the fourth quarter valued at $321,000. Bank of New York Mellon Corp boosted its stake in Blueprint Medicines by 2.4% in the fourth quarter. Bank of New York Mellon Corp now owns 303,432 shares of the biotechnology company’s stock valued at $26,465,000 after acquiring an additional 7,101 shares in the last quarter. KBC Group NV grew its holdings in shares of Blueprint Medicines by 63.9% during the fourth quarter. KBC Group NV now owns 2,625 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 1,023 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Blueprint Medicines during the fourth quarter worth about $21,104,000.

Insider Buying and Selling at Blueprint Medicines

In other news, COO Christina Rossi sold 2,274 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $110.14, for a total value of $250,458.36. Following the sale, the chief operating officer now directly owns 67,109 shares in the company, valued at $7,391,385.26. This represents a 3.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ariel Hurley sold 2,250 shares of Blueprint Medicines stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $100.00, for a total value of $225,000.00. Following the sale, the insider now owns 14,967 shares of the company’s stock, valued at approximately $1,496,700. This represents a 13.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 31,608 shares of company stock valued at $3,319,587 over the last quarter. Corporate insiders own 4.21% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on BPMC. Jefferies Financial Group began coverage on Blueprint Medicines in a research report on Monday, March 17th. They set a “buy” rating and a $135.00 price target on the stock. StockNews.com downgraded shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Monday, March 3rd. Wolfe Research assumed coverage on shares of Blueprint Medicines in a research report on Tuesday, March 18th. They set an “outperform” rating on the stock. Stephens reaffirmed an “overweight” rating and issued a $140.00 target price on shares of Blueprint Medicines in a report on Thursday, January 2nd. Finally, Needham & Company LLC restated a “buy” rating and issued a $133.00 price target on shares of Blueprint Medicines in a research report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Blueprint Medicines has a consensus rating of “Moderate Buy” and a consensus target price of $124.95.

Blueprint Medicines Stock Down 2.9 %

BPMC opened at $85.94 on Wednesday. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. The company has a market cap of $5.49 billion, a price-to-earnings ratio of -79.57 and a beta of 0.58. Blueprint Medicines Co. has a one year low of $80.68 and a one year high of $121.90. The business’s fifty day moving average is $97.17 and its two-hundred day moving average is $94.05.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.